Rivera R, Vilarrasa E, Ribera M, Roe E, Kueder-Pajares T, Zayas AI, Martínez-Molina L, Mataix Díaz J, Rodríguez-Nevado IM, Usero-Bárcena T, de la Mano D, García-Donoso C, Olveira A, Guinea G, Martín-Vázquez V, Ferran M
Methotrexate (MTX) is frequently used in the treatment of moderate-to-severe psoriasis, however, there is limited data on health-related quality-of-life (HRQoL), psoriasis clinical outcomes and hepatic fibrosis in MTX-treated patients in routine clinical practice.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
